Document is current
Any future updates will be listed below
-
Authors
Storandt, Michael H.
Durani, Urshila
Stan, Daniela
Larson, Nicole
Loprinzi, Charles
Couch, Fergus
Olson, Janet E.
Khera, Nandita
Ruddy, Kathryn J.
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation
National Institute of Health (NR015259 (KJR))
- License Information
-
More Information
Article History
Received: 20 July 2022
Accepted: 12 November 2022
First Online: 19 December 2022
Declarations
:
: This research was approved by the Mayo Clinic Institutional Review Board.
: Consent was obtained from all who participated in the Mayo Clinic Breast Disease Registry at time of registry enrollment.
: N/A.
: Michael H. Storandt, Urshila Durani, Daniela Stan, Nicole Larson, Fergus Cough, Janet E. Olson, and Kathryn J. Ruddy report no disclosures. Charles Loprinzi reports personal fees from PledPharma, personal fees from Disarm Therapeutics, personal fees from Asahi Kasei, personal fees from Metys Pharmaceuticals, personal fees from OnQuality, personal fees from Mitsubishi Tanabe, personal fees from NKMax, personal fees from Novartis, personal fees from HengRui, personal fees from Nuro Bio, personal fees from Osmol Therapeutics, Inc., personal fees from Grunenthal, and personal fees from Genentech outside the submitted work. Nandita Khera reports consulting fees from Incyte for chronic GVHD study.
